A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

A novel ultrasound-derived score combined with liver stiffness measurement can identify both MASH and fibrosis, potentially ...

Lumbar CT attenuation measurements outperform MRI-derived vertebral bone quality scores for diagnosing osteopenia and ...

Visible hyperpigmentation may mask persistent erythema and should not be assumed to indicate resolved inflammation,’ ...

Hallmark signs of pediatric pneumonia, including crackles and decreased breath sounds, shows low reliability between ...

A prospective study shows that lower levels of physical exercise are consistently associated with a higher risk for common ...

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

In a phase 3 trial, adding a combo of two traditional Chinese meds to metformin reduced A1c and improved lipid measure in ...